For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$37.82
Thesis
Novo Nordisk markets the semaglutide products Ozempic and Wegovy for type 2 diabetes and obesity. As a diversified company, its incretin franchise sits alongside a broader diabetes and metabolic portfolio.
Catalysts
- Semaglutide supply and manufacturing expansion
- Next-generation incretin clinical readouts
- Label expansions for Ozempic and Wegovy
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 19Trial readoutClinicalTrials.gov
Phase 2 trial NCT06409130 of NNC0194-0499, cagrilintide and semaglutide in alcohol-related liver disease completed.
- Nov 19Trial readoutClinicalTrials.gov
Phase 3 trial NCT06065540 of CagriSema vs semaglutide/cagrilintide/placebo in T2D completed.
- Nov 16Trial readoutClinicalTrials.gov
Phase 3 trial NCT06588504 for dasiglucagon vs glucagon in hypoglycemia completed (Japan, T1D adults/adolescents)
- Nov 16OtherClinicalTrials.gov
Phase 3 trial NCT07220759 (cagrilintide, overweight/obesity + T2D) status updated to ACTIVE_NOT_RECRUITING.
- Nov 16Trial readoutClinicalTrials.gov
Phase 3 trial NCT04775082 (SCALE KIDS) for weight management in children with obesity updated to ACTIVE_NOT_RECRUITING status.
- Nov 12Trial initiationClinicalTrials.gov
Novo Nordisk Phase 3 trial NCT07931573 (AMBITION 3) for Zenagamtide vs semaglutide in T2D, status NOT_YET_RECRUITING.
- Nov 12Trial initiationClinicalTrials.gov
Novo Nordisk Phase 3 trial NCT07931495 of Zenagamtide in Type 2 diabetes, status NOT_YET_RECRUITING.
- Nov 12Trial initiationClinicalTrials.gov
Phase 3 trial NCT07931599 initiated (NOT_YET_RECRUITING) comparing Zenagamtide vs semaglutide in T2D patients on metformin/SGLT2i.